Sign In
Buy AXNX
$70.98
+0 (+0%)
At Close: Feb 13, 2025
Axonics Modulation Technologies (AXNX) Reports Q3 Loss, Tops Revenue Estimates
06:50pm, Monday, 31'st Oct 2022
Axonics (AXNX) delivered earnings and revenue surprises of 27.66% and 12.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Axonics (AXNX) This Earnings Season?
11:19am, Thursday, 27'th Oct 2022
Axonics (AXNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is Axonics (AXNX) Outperforming Other Medical Stocks This Year?
11:18am, Thursday, 13'th Oct 2022
Here is how Axonics Modulation Technologies (AXNX) and Molina (MOH) have performed compared to their sector so far this year.
Axonics® to Report Third Quarter 2022 Financial Results on October 31
06:00am, Monday, 10'th Oct 2022
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct
Leading Medical Stocks, Including Sensus And Shockwave, Have Grown At Least 36% This Year
01:18pm, Wednesday, 05'th Oct 2022
Biotech isn't the only place investors in health care stocks can make money in 2022. Take a look at leading medical-equipment stocks.
Has Axonics (AXNX) Outpaced Other Medical Stocks This Year?
11:17am, Monday, 26'th Sep 2022
Here is how Axonics Modulation Technologies (AXNX) and Molina (MOH) have performed compared to their sector so far this year.
Axonics: Medical Devices Play
06:46pm, Thursday, 15'th Sep 2022
100% technical buy signals. 7 new highs and up 5.40% in the last month.
Medical Device Maker Announces New Patients, Shoots Past Buy Point
03:37pm, Thursday, 08'th Sep 2022
Axonics is breaking out from a three-weeks-tight pattern after announcing it has begin treating patients in Canada. The post Medical Device Maker Announces New Patients, Shoots Past Buy Point appeared
Axonics Stock Is A Buy Amid Current Capex Cycle
11:41am, Wednesday, 07'th Sep 2022
Axonics looks well-positioned to continue its recent upside on the chart, with a number of idiosyncratic tailwinds yet to be recognized. The recent equity underwriting of $35mm is noted, although this
Medical Stock Shows Strength In A Weakening Market; Nears Buy Point
03:58pm, Thursday, 01'st Sep 2022
Medical device stock Axonics is near the buy point of a new basing pattern, which presents the potential for price gains ahead. The post Medical Stock Shows Strength In A Weakening Market; Nears Buy P
Are Medical Stocks Lagging Axonics (AXNX) This Year?
11:18am, Monday, 22'nd Aug 2022
Here is how Axonics Modulation Technologies (AXNX) and Assertio (ASRT) have performed compared to their sector so far this year.
Axonics® to Participate in September Investor Conferences
06:00am, Thursday, 18'th Aug 2022
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct
Here's Why Axonics Modulation Technologies (AXNX) is a Great Momentum Stock to Buy
01:33pm, Monday, 08'th Aug 2022
Does Axonics Modulation Technologies (AXNX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Axonics (AXNX) Stock Outpacing Its Medical Peers This Year?
11:18am, Thursday, 04'th Aug 2022
Here is how Axonics Modulation Technologies (AXNX) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.
Axonics, Inc. (AXNX) CEO Raymond Cohen on Q2 2022 Results - Earnings Call Transcript
10:30pm, Monday, 01'st Aug 2022
Axonics, Inc. (NASDAQ:AXNX ) Q2 2022 Earnings Conference Call August 1, 2022 4:30 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - Pr
